CELC
Celcuity Inc.- Healthcare
- Biotechnology
- $4.07B market cap
Forecast run · Sep 14, 2026Upside rank 830 of 3,136
Model Signal
ForecastQ Daily Probabilities
48.3%
22.5%
26.9%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$83.45
Price target$159.88
Implied move+91.6%
Analysts12
ForecastQ Portfolios
CELC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.